A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Phase 4
Completed
- Conditions
- Cancer of Prostate
- Registration Number
- NCT00220194
- Lead Sponsor
- San Bernardino Urological Associates Medical Group Inc
- Brief Summary
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Patient with Advanced Ca, on stable dose of Lupron or Zoladex
Exclusion Criteria
- Previous exposure to Eligard.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Eligard maintains serum testosterone suppression in prostate cancer patients compared to Lupron and Zoladex?
How does the efficacy of Eligard in PSA suppression compare to standard-of-care LHRH agonists like Lupron and Zoladex in advanced prostate cancer?
Which biomarkers are associated with response to LHRH agonist therapies such as Eligard, Lupron, and Zoladex in castration-resistant prostate cancer?
What are the potential adverse events and management strategies when switching from Lupron/Zoladex to Eligard in hormone-sensitive prostate cancer?
How do combination approaches involving Eligard and other androgen receptor pathway inhibitors compare to monotherapy in metastatic prostate cancer?
Trial Locations
- Locations (1)
San bernardino Urological Associates Medical Group
🇺🇸San Bernardino, California, United States
San bernardino Urological Associates Medical Group🇺🇸San Bernardino, California, United States